Test Price
4,800 AED✅ Home Collection Available
Cardiac Channelopathy Gene Panel in UAE | 4800 AED | DHA Licensed
Executive Summary & Core Metrics
- Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO-Accredited Next‑Generation Sequencing (NGS) processing.
- Collection Logistics: Hospital Extraction Only – Sample collection is conducted strictly within an accredited hospital facility; mobile home phlebotomy is disabled for safety.
- Clinical Guidance: Complimentary telephonic post‑test clinical interpretation and genetic counsellor support.
- Insurance: Direct Billing Verification via WhatsApp: +971 54 548 8731.
Test Overview & Methodology
The Cardiac Channelopathy Gene Panel is a comprehensive NGS screen that identifies pathogenic variants in over 30 cardiac ion channel genes associated with inherited arrhythmia syndromes and sudden cardiac death.
| Feature | Our NGS Panel | Closest Alternative (Single‑Gene Sanger) |
|---|---|---|
| Precision | >99.9% sensitivity for 34+ genes | High per‑gene, but misses other linked channelopathies |
| Methodology | Next‑Generation Sequencing (NGS) with full CNV analysis | Sanger sequencing – single gene, no CNV detection |
| Turnaround Time | 4–6 weeks | 6–8 weeks per gene |
| Sample Collection | Hospital-only (blood, amniotic fluid, chorionic villi) | Clinic or hospital only |
| Cost (AED) | 4,800 | 1,800–2,500 per gene (cumulative cost often exceeds 5,000) |
Physician Insight & Safety Protocols
“As a clinical geneticist, I understand the complex implications of inherited cardiac risks. This panel provides a powerful molecular diagnosis, but results must be interpreted alongside family history and clinical evaluation. Our team offers comprehensive post-test counselling to guide you through every step.”
— Lina Osama Zaki Quteineh, Consultant Medical Genetics (DHA Registration ID: 9294403)
⚠️ Important Medication Advisory
Do not discontinue any prescribed medication without consulting your doctor. Genetic results should never replace clinical judgement or ongoing therapy.
Patient Safety & Exclusion Criteria
- Exclusion Criteria: Known severe bleeding disorder; acute myocardial infarction within 72 hours; haemodynamic instability (systolic BP <90 mmHg).
- Prenatal Sampling: Amniocentesis/CVS performed only after detailed ultrasound assessment; active vaginal bleeding or ruptured membranes are contraindications.
- Emergency Red Flags: Seek immediate emergency care if you experience sudden chest pain, syncope (fainting) with palpitations, or seizure‑like activity before or after sample collection.
- Data Privacy: All genetic data handled in full compliance with UAE PDPL (Federal Decree‑Law No. 45 of 2021) and Federal Law No. 2 of 2019 concerning Use of ICT in Health Fields.
Patient FAQ & Clinical Guidance
1. What does the Cardiac Channelopathy Gene Panel detect?
This gene panel identifies pathogenic variants in over 30 cardiac ion channel genes linked to sudden cardiac death. It provides a definitive molecular diagnosis for conditions such as Long QT syndrome (KCNQ1, KCNH2, SCN5A), Brugada syndrome, and catecholaminergic polymorphic ventricular tachycardia (RYR2, CASQ2).
2. Who should consider this genetic test?
Individuals with unexplained syncope, family history of sudden cardiac death, or suspected inherited arrhythmia should undergo this. It is also recommended for asymptomatic relatives of a mutation‑positive proband and for patients with drug‑induced QT prolongation to rule out silent channelopathy.
3. How is the sample collected and when will I receive results?
A peripheral blood draw, amniotic fluid, or chorionic villi sample is taken, with results available in 4–6 weeks. Sample collection is conducted strictly within an accredited hospital facility; mobile home phlebotomy is disabled for safety. You will receive a secure online report with clinical interpretation support.
UAE Regulatory & Data Privacy Adherence
DHA Facility License: 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE
All testing adheres to UAE PDPL, Federal Law No. 2 of 2019, and Federal Decree‑Law No. 4 of 2016. Methodology: NGS (LC‑MS/MS backup for metabolite screening not applicable).
Clinical & Logistical Metadata
| Test Name | Cardiac Channelopathy Gene Panel |
| Price (AED) | 4,800 |
| Turnaround Time | 4 – 6 weeks |
| Sample Type / Matrix | Peripheral blood, Amniotic fluid, Chorionic villi |
| Methodology Used | Next‑Generation Sequencing (NGS) with CNV analysis |
| ICD-10-CM Code | I49.9 (Cardiac arrhythmia, unspecified) |
| LOINC Code | 81311-2 (Cardiac channelopathy gene panel) |
| DHA Facility License & Address | 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE | DNA Labs UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians